CA Patent

CA3031777A1 — Crystalline form of olaparib

Assigned to Apotex Inc · Expires 2019-07-31 · 7y expired

What this patent protects

The present invention provides a novel crystalline form of Olaparib comprising Olaparib and benzyl alcohol, compositions thereof, and the use of this crystalline form in the treatment of cancers, such as germline BRCA-mutated (gBRCAm) advanced ovarian cancer.

USPTO Abstract

The present invention provides a novel crystalline form of Olaparib comprising Olaparib and benzyl alcohol, compositions thereof, and the use of this crystalline form in the treatment of cancers, such as germline BRCA-mutated (gBRCAm) advanced ovarian cancer.

Drugs covered by this patent

Patent Metadata

Patent number
CA3031777A1
Jurisdiction
CA
Classification
—
Expires
2019-07-31
Drug substance claim
No
Drug product claim
No
Assignee
Apotex Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.